PetMed Express Files 8-K on Financials and Listing Status
Ticker: PETS · Form: 8-K · Filed: Nov 13, 2025 · CIK: 1040130
| Field | Detail |
|---|---|
| Company | Petmed Express Inc (PETS) |
| Form Type | 8-K |
| Filed Date | Nov 13, 2025 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-condition, listing-rule, exhibits
Related Tickers: PETS
TL;DR
PETS filed an 8-K detailing financial results and potential listing issues.
AI Summary
PetMed Express, Inc. filed an 8-K on November 13, 2025, reporting on its results of operations and financial condition. The filing also addresses a notice of delisting or failure to satisfy a continued listing rule and includes financial statements and exhibits. The report covers events as of November 12, 2025.
Why It Matters
This filing provides crucial updates on PetMed Express's financial health and its compliance with stock exchange listing requirements, which could impact investor confidence and stock valuation.
Risk Assessment
Risk Level: medium — The filing mentions a notice of delisting or failure to satisfy a continued listing rule, which indicates potential significant risks for the company.
Key Players & Entities
- PETMED EXPRESS INC (company) — Registrant
- November 12, 2025 (date) — Date of earliest event reported
- November 13, 2025 (date) — Date of report
- 420 South Congress Avenue, Delray Beach, Florida 33445 (address) — Principal executive offices
FAQ
What specific financial results are being reported in this 8-K?
The filing indicates it covers 'Results of Operations and Financial Condition' but does not provide specific figures within the provided text.
What is the nature of the 'Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard'?
The filing states this notice was issued but does not detail the specific rule or standard that was not met.
When did the events reported in this filing occur?
The earliest event reported occurred on November 12, 2025.
What is the primary business of PetMed Express, Inc.?
PetMed Express, Inc. is identified under the Standard Industrial Classification as 'RETAIL-DRUG STORES AND PROPRIETARY STORES [5912]'.
Where are PetMed Express, Inc.'s principal executive offices located?
The principal executive offices are located at 420 South Congress Avenue, Delray Beach, Florida 33445.
Filing Stats: 1,246 words · 5 min read · ~4 pages · Grade level 13.5 · Accepted 2025-11-13 08:31:59
Filing Documents
- pets-20251112.htm (8-K) — 35KB
- petsannouncesf2q26prelimin.htm (EX-99.1) — 12KB
- 0001040130-25-000086.txt ( ) — 207KB
- pets-20251112.xsd (EX-101.SCH) — 2KB
- pets-20251112_def.xml (EX-101.DEF) — 16KB
- pets-20251112_lab.xml (EX-101.LAB) — 27KB
- pets-20251112_pre.xml (EX-101.PRE) — 16KB
- pets-20251112_htm.xml (XML) — 4KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On November 13, 2025, PetMed Express, Inc. (the "Company") issued a press release announcing preliminary estimated revenues for the three- and nine-month periods ended September 30, 2025. These preliminary estimated revenues are unaudited, based on currently available information and do not present all necessary information for a complete understanding of the Company's financial condition as of September 30, 2025, or its results of operations for the three- and nine-month periods ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein. The information furnished in this Item 2.02 on this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, regardless of any general incorporation language in such filing.
01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On November 12, 2025, the Company received an expected notice (the "Notice") from the Nasdaq Stock Market LLC ("Nasdaq"), which indicated that, as a result of the Company's delay in filing its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2025 (the "Q2 10-Q"), in addition to its continued delinquency in filing its Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2025 (the "Q1 10-Q"), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Listing Rule"), which requires Nasdaq-listed companies to timely file all required periodic financial reports with the U.S. Securities and Exchange Commission (the "SEC"). The Notice further states that, because the Company was delinquent in filing its Form 10-K for the fiscal year ended March 31, 2025 (the "Initial Delinquent Filing") and remains delinquent in filing the Q1 10-Q, any Nasdaq Staff exception to allow the Company to regain compliance, if granted, will be limited to a maximum of 180 calendar days from the due date of the Initial Delinquent Filing, or December 29, 2025. The Notice states that, as a result of the additional delinquency, the Company must submit, by November 28, 2025, an update to its original plan to regain compliance with respect to the filing requirement. The Company previously submitted its original plan to regain compliance to Nasdaq on September 2, 2025, and the Company intends to timely update Nasdaq with respect to the plan by November 28, 2025. The Notice has no immediate effect on the listing of the Company's common stock on Nasdaq. While the Company can provide no assurances as to timing, the Company continues to work diligently to complete its Q1 10-Q and Q2 10-Q and intends to file them as promptly as possible to regain compliance with the Listing Rule.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) Cautionary Note Regarding Forward-Looking Statements This Current Report on Form 8-K contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements. Words such as "may," "could," "expect," "project," "outlook," "strategy," "intend," "plan," "seek," "anticipate," "believe," "estimate," "predict," "potential," "strive," "goal," "continue," "likely," "will," "would" and other similar words and expressions are intended to signify forward-looking statements. Such forward-looking statements are necessarily based upon estimates and assumptions that, while considered reasonable by the Company and its management, are inherently uncertain and are subject to various risks and uncertainties, 2 including: the Company's ability to complete the filing of its Q1 10-Q and Q2 10-Q within the anticipated time period; the Company's ability to regain compliance with Nasdaq listing standards; and the time and effort required to complete and file the Company's financial statements and Form 10-Qs for its fiscal quarters ending June 30, 2025, and September 30, 2025. The Company's future results may also be impacted by other risk factors listed from time to time in the Company's filings with the SEC, including, but not limited to, the Company's Annual Report on Form 10-K for the year ended March 31, 2025, as well as other subsequent filings on Form 10-Q and periodic filings on Form 8-K. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this Current Report on Form 8-
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: November 13, 2025 PETMED EXPRESS, INC. By: /s/ Douglas Krulik Name: Douglas Krulik Title: Chief Accounting Officer, Interim Principal Financial Officer and Treasurer 4